Patents Issued in June 16, 2016
  • ANTIFUGETACTIC AGENTS FOR THE TREATMENT OF BRAIN CANCERS
    Publication number: 20160166537
    Abstract: This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides antifugetactic agents and methods for the use thereof in enhancing an immune response.
    Type: Application
    Filed: November 9, 2015
    Publication date: June 16, 2016
    Applicant: The General Hospital Corporation dba Massachusetts General Hospital
    Inventors: MARK C. POZNANSKY, JOHN T. POTTS, Jr., FABRIZIO VIANELLO, NATALIA PAPETA
  • ANTIFUGETACTIC AGENTS FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20160166538
    Abstract: This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response.
    Type: Application
    Filed: November 9, 2015
    Publication date: June 16, 2016
    Applicant: The General Hospital Corporation dba Massachusetts General Hospital
    Inventors: MARK C. POZNANSKY, JOHN T. POTTS, JR., FABRIZIO VIANELLO, NATALIA PAPETA
  • A NOVEL COMPOSITION FOR NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Publication number: 20160166539
    Abstract: The present invention provides a compound of Formula (I) or pharmaceutical acceptable thereof, wherein ‘R’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (I) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).
    Type: Application
    Filed: June 25, 2013
    Publication date: June 16, 2016
    Inventors: Pankaj PATEL, Rajendrakumar Hariprasad Jani
  • MODULATORS FOR ATP-BINDING CASSETTE TRANSPORTERS
    Publication number: 20160166540
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: January 11, 2016
    Publication date: June 16, 2016
    Inventors: Adam Looker, Benjamin Joseph Littler, Anusuya Choudhury, Christian Harrison, Ravikanth Veluri, Michael P. Ryan, Licong Jiang, Eduard Luss-Lusis
  • Methods For Identifying Analgesic Agents
    Publication number: 20160166541
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.
    Type: Application
    Filed: January 27, 2016
    Publication date: June 16, 2016
    Applicant: Xenon Pharmaceutical Inc.
    Inventors: Marcia MacDonald, Mark Samuels, Robin Sherrington, Yigal Paul Goldberg
  • INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE
    Publication number: 20160166542
    Abstract: The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.
    Type: Application
    Filed: February 22, 2016
    Publication date: June 16, 2016
    Inventors: Hanlan Liu, Chris Willis, Renu Bhardwaj, Diane P. Copeland, Abizer Harianawala, Jeffrey Skell, John Marshall, Jianmei Kochling, Gerard Palace, Judith Peterschmitt, Craig Siegel, Seng Cheng
  • STABLE COMBINATION ORAL LIQUID FORMULATION OF MELATONIN AND AN ANTIHISTAMINIC AGENT
    Publication number: 20160166543
    Abstract: A combination oral liquid formulation of melatonin with a antihistaminic drug has been proposed as a sleep-aid agent. The solubility and stability of melatonin was improved by using cyclodextrin and adjusting the pH to a suitable value. The combination drug is expected to have a dual mode of action. The antihistaminic agent may help patient to fall asleep quickly and melatonin may be effective subsequently providing a sound sleep to the patient.
    Type: Application
    Filed: December 10, 2014
    Publication date: June 16, 2016
    Inventors: Hemant N. JOSHI, Samir H. PATEL
  • ORAL PHARMACEUTICAL FORMULATION OF OMARIGLIPTIN
    Publication number: 20160166544
    Abstract: The present invention is directed to stable, oral pharmaceutical formulations of dipeptidyl peptidase-4 inhibitors, such as omarigliptin. Such pharmaceutical formulations comprise omarigliptin; and neutral excipients, wherein the neutral excipient is present in the amount of at least 75% by weight of the pharmaceutical formulation and comprises at least one non-reducible sugar diluent or a mixture of non-reducible sugar diluents.
    Type: Application
    Filed: August 25, 2014
    Publication date: June 16, 2016
    Inventors: Vincent Brett Cooper, Kathryn Alanna Bradley, Samuel Robert Pygall, Rajan Gupta, Madison Paige Stanford, Lin Xie
  • COMBINATIONS COMPRISING BIPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF HCV
    Publication number: 20160166545
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Application
    Filed: July 15, 2014
    Publication date: June 16, 2016
    Inventors: Mark G. Saulnier, David B. Frennesson, Makonen Belema
  • COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF
    Publication number: 20160166546
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.
    Type: Application
    Filed: July 25, 2014
    Publication date: June 16, 2016
    Inventors: William J. GARNER, Amie FRANKLIN, John ROTHMAN
  • Combinations Comprising Tricyclohexadecahexaene Derivatives for Use in the Treatment of Hepatitis C Virus
    Publication number: 20160166547
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Application
    Filed: July 15, 2014
    Publication date: June 16, 2016
    Inventors: Alan Xiangdong Wang, Omar D. Lopez, Yong Tu, Makonen Belema
  • ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS
    Publication number: 20160166548
    Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
    Type: Application
    Filed: December 15, 2015
    Publication date: June 16, 2016
    Applicant: Novartis AG
    Inventors: Jiping FU, Xianming JIN, Subramanian KARUR, Guillaume LAPOINTE, Ann Marie MADERA, Zachary Kevin SWEENEY
  • BCL6 INHIBITORS AS ANTICANCER AGENTS
    Publication number: 20160166549
    Abstract: The invention provides compositions and methods for blocking the BCL6 BTB domain with small molecule, non-peptide compounds as disclosed and claimed herein. BCL6 is a transcriptional repressor of the BTB-POZ (brie a brae, tramtrack, broad complex/pox virus zincfinger) family of proteins. It is required for normal development of germinal center (GC) B-cells and is also the most commonly involvedoncogene in diffuse large B-celllymphomas (DLBCLs), and constitutive expression of BCL6 in GC B-cells causes DLBCL in mice.
    Type: Application
    Filed: June 16, 2014
    Publication date: June 16, 2016
    Inventors: Ari Melnick, Leandro Carlos A. Cerchietti, Mariano G. Cardenas, Fengtian Xue, Alexander D. MacKerell
  • Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders
    Publication number: 20160166550
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Application
    Filed: February 19, 2016
    Publication date: June 16, 2016
    Inventor: David R. Elmaleh
  • Solid dispersions comprising tacrolimus
    Publication number: 20160166551
    Abstract: A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.
    Type: Application
    Filed: November 6, 2015
    Publication date: June 16, 2016
    Inventor: Per HOLM
  • PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES
    Publication number: 20160166552
    Abstract: A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.
    Type: Application
    Filed: January 18, 2016
    Publication date: June 16, 2016
    Inventors: Cheol Young Maeng, Young Koo Jang, Su Bong Cha, Hye Won Shin, Chan Mi Joung, Eun Jung Yi
  • ANTIMETASTATIC COMPOUNDS
    Publication number: 20160166553
    Abstract: Screening methods for identifying compounds and compounds and pharmaceutical compositions for treating and preventing cancer are disclosed. The compounds affect signal transduction downstream of the MET receptor.
    Type: Application
    Filed: February 18, 2016
    Publication date: June 16, 2016
    Inventor: Marc Hansen
  • COMPOSITION COMPRISING HYALURONIC ACID AND MEPIVACAINE
    Publication number: 20160166554
    Abstract: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.
    Type: Application
    Filed: February 16, 2016
    Publication date: June 16, 2016
    Inventors: Francois Bourdon, Stephane Meunier
  • Cyclooxygenase Inhibitor and Calcium Channel Antagonist Compositions and Methods for Use in Urological Procedures
    Publication number: 20160166555
    Abstract: Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing agents and a buffering agent.
    Type: Application
    Filed: November 20, 2015
    Publication date: June 16, 2016
    Inventors: Gregory A. Demopulos, Jeffrey M. Herz
  • METHODS OF TREATING PULMONARY HYPERTENSION
    Publication number: 20160166556
    Abstract: The present disclosure relates to a method of preventing and/or treating pulmonary vascular disease and/or right ventricular dysfunction, including but not limited to pulmonary hypertension or pulmonary arterial hypertension, comprising administering a therapeutically effective amount of an ASK1 inhibitor.
    Type: Application
    Filed: August 11, 2015
    Publication date: June 16, 2016
    Inventors: Grant Raymond Budas, John T. Liles, Dillon Thanh Phan
  • ANTIVIRAL AGENTS
    Publication number: 20160166557
    Abstract: A method for treating or preventing a norovirus, such as Norwalk virus, infection in a subject, which comprises administering to said subject in need thereof a therapeutically effective amount of at least one compound selected from the group consisting of: a pharmaceutically acceptable salt thereof or solvate thereof or mixtures thereof. The subject can be an animal, particularly mammals and more particularly humans and companion animals such as cats and dogs.
    Type: Application
    Filed: December 8, 2015
    Publication date: June 16, 2016
    Inventor: Mark J. Suto
  • METHOD FOR TREATING A PATIENT AT RISK FOR DEVELOPING AN NSAID-ASSOCIATED ULCER
    Publication number: 20160166558
    Abstract: The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof to said at risk patient and thereby decreasing the patient's risk of developing an ulcer.
    Type: Application
    Filed: February 23, 2016
    Publication date: June 16, 2016
    Applicants: POZEN INC., HORIZON PHARMA USA, INC.
    Inventors: Brian AULT, Clara HWANG, Everardus Orlemans, John R. PLACHETKA, Mark SOSTEK
  • DEUTERATED ANALOGS OF PRIDOPIDINE USEFUL AS DOPAMINERGIC STABILIZERS
    Publication number: 20160166559
    Abstract: In other aspects the invention relates to pharmaceutical compositions comprising a deuterated analog of Pridopidine of the invention, and to therapeutic applications of these analogs.
    Type: Application
    Filed: December 14, 2015
    Publication date: June 16, 2016
    Applicant: Teva Pharmaceuticals International GmbH
    Inventor: Clas SONESSON
  • Urea Compounds and Their Use as FAAH Enzyme Inhibitors
    Publication number: 20160166560
    Abstract: A compound having Formula I: wherein: R1 is selected from hydrogen, halogen, hydroxyl and C1-4 alkoxy; R2 is selected from hydrogen, halogen, hydroxyl and C1-4 alkoxy; R3 is C1-4 alkyl; R4 is aryl which is substituted with a group selected from OSO2NH2, NHCONH2, NHSO2NH2, NHSO2C1-4 alkyl and CONH2; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; provided that the compound is not N-(1-benzylpiperidin-4-yl)-N-methyl-4-(4-(sulfamoylamino)phenyl)-1H-imidazole-1-carboxamide or N-(1-benzylpiperidin-4-yl)-N-methyl-4-(3-(methyl sulfonamido)phenyl)-1H-imidazole-1-carboxamide. The compound may be used as an inhibitor of fatty acid amide hydrolase.
    Type: Application
    Filed: August 1, 2014
    Publication date: June 16, 2016
    Inventors: Laszlo Erno Kiss, Rita Gusmão De Noronha, Carla Patrícia Da Costa P Rosa, Rui Pinto
  • ANTIPSYCHOTIC TREATMENT BASED ON DRD2 OR ANKK1 SNP GENOTYPE
    Publication number: 20160166561
    Abstract: The present invention relates to the treatment of an individual with an antipsychotic based on individual's genotype at one or more single nucleotide polymorphism (SNP) associated with the dopamine receptor D2 (DRD2) and/or ankyrin repeat and kinase domain containing 1 (ANKK1) genes.
    Type: Application
    Filed: December 12, 2015
    Publication date: June 16, 2016
    Inventors: Christian Lavedan, Simona Volpi
  • DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES
    Publication number: 20160166562
    Abstract: Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds corresponding to general formula (I) are disclosed. Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases.
    Type: Application
    Filed: May 8, 2015
    Publication date: June 16, 2016
    Inventors: Branislav MUSICKI, Jerôme AUBERT, Patricia ROSSIO, Marlène SCHUPPLI-NOLLET, Laurence CLARY, Jean-Guy BOITEAU
  • Anti-Allergy Benzocycloheptathiophene Derivatives
    Publication number: 20160166563
    Abstract: The present invention provides a method for treating an allergy disease or disorder or symptoms related thereto, in a subject in need thereof, the method comprising: administering a therapeutically effective amount of an anti-allergy benzocycloheptathiophene derivative compound of Formula I: or a pharmaceutically acceptable salt thereof, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier, vehicle or excipient.
    Type: Application
    Filed: February 19, 2016
    Publication date: June 16, 2016
    Inventors: Tongjun Lin, Jun Xin
  • Nicotine Salt with Meta-Salicylic Acid
    Publication number: 20160166564
    Abstract: The present disclosure relates generally to the field of nicotine delivery. The disclosure teaches a nicotine meta-salicylate. More specifically, the disclosure teaches a condensation nicotine aerosol where nicotine meta-salicylate is vaporized. This disclosure relates to aerosol nicotine delivery devices. The delivery devices can be activated by actuation mechanisms to vaporize thin films comprising a nicotine meta-salicylate. More particularly, this disclosure relates to thin films of nicotine salt with meta salicylic acid for the treatment of nicotine craving and for effecting smoking cessation.
    Type: Application
    Filed: July 11, 2014
    Publication date: June 16, 2016
    Inventors: Daniel J. MYERS, James CASSELLA
  • TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FLUPIRTINE
    Publication number: 20160166565
    Abstract: This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with flupirtine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and flupirtine for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with flupirtine in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and flupirtine in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.
    Type: Application
    Filed: February 12, 2016
    Publication date: June 16, 2016
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: David Silver, Einat Amit Romach
  • SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES
    Publication number: 20160166566
    Abstract: The present invention is directed to crystalline addition salts of (ii) 8-hydroxyquinolin-2(1H)-one derivatives and (ii) a dicarboxylic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.
    Type: Application
    Filed: July 24, 2014
    Publication date: June 16, 2016
    Inventors: Montserrat JULIA JANE, Francesc CARRERA CARRERA, Maria PRAT QUIÑONES, Carlos PUIG DURAN, Francesca PAJUELO LORENZO, Juan Antonio PEREZ ANDRES
  • TREATMENT OF CANCER
    Publication number: 20160166567
    Abstract: Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.
    Type: Application
    Filed: July 15, 2015
    Publication date: June 16, 2016
    Applicant: CERULEAN PHARMA INC.
    Inventor: John Ryan
  • METHODS AND COMPOSITIONS FOR CORRECTION OF ORGAN DYSFUNCTION
    Publication number: 20160166568
    Abstract: The present invention includes compositions and methods for treating certain conditions, the composition comprising a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine, wherein the composition is used to treat at least one of autonomic dysfunctions or vascular diseases.
    Type: Application
    Filed: February 23, 2016
    Publication date: June 16, 2016
    Inventor: Diana Driscoll
  • METHOD FOR TREATING SKIN THICKENING
    Publication number: 20160166569
    Abstract: Methods, compositions and products for treating or reducing skin thickening in a subject are described. Also described are methods of inhibiting a skin disorder induced by an UV-irradiation. The methods involve topically administering to the subject a composition containing an et adrenergic receptor agonist, such as brimonidine.
    Type: Application
    Filed: July 28, 2014
    Publication date: June 16, 2016
    Applicant: Galderma Research and Development
    Inventor: Guy BOUVIER
  • TREATMENT OR PREVENTION OF NON-INFLAMMATORY NEURONAL DAMAGE FROM BRAIN TRAUMA AND STROKES USING MENTHOL, LINALOOL AND/OR ICILIN
    Publication number: 20160166570
    Abstract: Compositions for prevention or treatment of non-inflammatory neuronal damage from brain trauma and strokes are provided, and the compositions contain a therapeutically effective amount of a compound selected from the group consisting of Menthol, Linalool, Icilin and combinations thereof. Methods for treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes are also provided, and the methods include administering such compositions.
    Type: Application
    Filed: May 23, 2014
    Publication date: June 16, 2016
    Inventors: Susana Camacho, Stephanie Michlig Gonzalez, Johannes Le Coutre, Henry Markram, Maurizio Pezzoli
  • COMBINATION THERAPIES FOR TREATMENT OF CANCER
    Publication number: 20160166571
    Abstract: Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.
    Type: Application
    Filed: September 18, 2015
    Publication date: June 16, 2016
    Inventors: Matthew Robert Janes, Matthew Peter Patricelli, Liansheng Li, Pingda Ren, Yi Liu
  • BENEFICIAL EFFECTS OF Lp-PLA2 INHIBITORS IN TREATMENT OF DIABETIC RETINOPATHY AND AGE-RELATED MACULAR DEGENERATION
    Publication number: 20160166572
    Abstract: The present invention relates to methods of detecting, diagnosing and treating diseases and disorders associated with increased BBB and BRB permeability.
    Type: Application
    Filed: December 10, 2015
    Publication date: June 16, 2016
    Applicant: Rowan University
    Inventor: Robert G. Nagele
  • COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF HYPERURICEMIA RELATED HEALTH CONSEQUENCES
    Publication number: 20160166573
    Abstract: Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods that involve administering to a patient susceptible to development of diabetes a composition comprising a uric acid lowering agent in a regimen that maintains serum uric acid levels below at least 5.5 mg/dl, or below at least 5.2 mg/dl.
    Type: Application
    Filed: October 12, 2015
    Publication date: June 16, 2016
    Inventors: Richard Johnson, Takahiko Nakagawa
  • MACROCYCLES AS KINASE INHIBITORS
    Publication number: 20160166574
    Abstract: Compounds of the formula I in which X, Y, Q1, M, Q2 and B have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: April 9, 2014
    Publication date: June 16, 2016
    Applicant: Merck Patent Gmbh
    Inventors: Guenter HOELZEMANN, Dieter DORSCH, Ansgar WEGENER, Oliver POESCHKE, Michael BUSCH
  • PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
    Publication number: 20160166575
    Abstract: The present invention relates to 6-amino-7-deaza-purine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular RET family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions containing these compounds.
    Type: Application
    Filed: May 7, 2014
    Publication date: June 16, 2016
    Inventors: Mauro Angiolini, Laura Buffa, Maria Menichincheri, Ilaria Motto, Paolo Polucci, Gabriella Traquandi, Fabio Zuccotto
  • SUBSTITUTED AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES (IRAK-4)
    Publication number: 20160166576
    Abstract: This invention relates to amidopyrazole compounds that are inhibitors of Interieukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment of cellular proliferative diseases. Speifically (5-methylpyridin-2-yl)-1 H-pyrazol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives are disclosed for use in the method of treating inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease and cancer.
    Type: Application
    Filed: July 7, 2014
    Publication date: June 16, 2016
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Jongwon LIM, Michael D. ALTMAN
  • TREATMENT OF PULMONARY FIBROSIS USING AN INHIBITOR OF CBP/CATENIN
    Publication number: 20160166577
    Abstract: The present disclosure relates generally to alpha-helix mimetic structures and specifically to alpha-helix mimetic structures that are inhibitors of ?-catenin. The disclosure also relates to applications in the treatment of pulmonary fibrosis, including usual interstitial pneumonia and idiopathic pulmonary fibrosis, and pharmaceutical compositions comprising such alpha helix mimetic ?-catenin inhibitors.
    Type: Application
    Filed: October 21, 2013
    Publication date: June 16, 2016
    Applicant: PRISM PHARMA CO., LTD.
    Inventors: Hiroyuki KOUJI, Takenao ODAGAMI
  • METHOD FOR TREATING TYPE I AND TYPE II DIABETES
    Publication number: 20160166578
    Abstract: The present disclosure relates generally to alpha-helix mimetic structures and specifically to alpha-helix mimetic structures that are inhibitors of ?-catenin. The disclosure also relates to applications in the treatment of diabetes and diabetic conditions such as diabetic neuropathy, and pharmaceutical compositions comprising such alpha helix mimetic ?-catenin inhibitors.
    Type: Application
    Filed: October 21, 2013
    Publication date: June 16, 2016
    Applicant: PRISM PHARMA CO., LTD.
    Inventors: Hiroyuki KOUJI, Takenao ODAGAMI
  • COMBINATION METHODS FOR TREATING CANCERS
    Publication number: 20160166579
    Abstract: Disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I: or a pharmaceutically acceptable salt thereof; in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer and may not respond to either agent administered as a sole therapy. The subject who has the cancer may also be refractory to at least one chemotherapy treatment, or is in relapse after treatment with chemotherapy, or both. The cancer may be a hematologic malignancy, such as leukemia or lymphoma, or a solid tumor cancer, such as pancreatic, lung and colon cancer.
    Type: Application
    Filed: July 10, 2015
    Publication date: June 16, 2016
    Inventors: Julie Di Paolo, Astrid Clarke
  • FORMULATION OF SYK INHIBITORS
    Publication number: 20160166580
    Abstract: Disclosed are pharmaceutical compositions comprising a compound having the formula: or a pharmaceutically acceptable salt thereof, or a hydrate of thereof, and at least one pharmaceutically acceptable polymer. The pharmaceutically acceptable salt of the compound of Formula I, or a hydrate thereof, can be a mesylate salt, including, for example, a mono-mesylate or a bis-mesylate salt, or a hydrate thereof. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Application
    Filed: July 29, 2014
    Publication date: June 16, 2016
    Inventors: Melissa Jean Casteel, Bei Li, Rowchanak Pakdaman, Diana Sperger, Dimitrios Stefanidis
  • Method for Treating Equine Metabolic Syndrome, Feline Diabetes and Feline Renal Disease
    Publication number: 20160166581
    Abstract: There is disclosed a method for treating Equine Metabolic Syndrome (EMS) comprising administering an acetyl cholinesterase inhibitor compound to the suspected EMS horse. The present disclosure further provides a method for treating feline or canine diabetes and feline or canine renal disease comprising administering an acetyl cholinesterase inhibitor compound to the suspected feline or canine.
    Type: Application
    Filed: December 16, 2014
    Publication date: June 16, 2016
    Inventor: Stephen Wills
  • PROTEASOME INHIBITORS AND USES THEREOF
    Publication number: 20160166582
    Abstract: A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors.
    Type: Application
    Filed: February 23, 2016
    Publication date: June 16, 2016
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Irina LAVELIN, Varda ROTTER, Moshe OREN, Ami NAVON, Zvi KAM, Benjamin GEIGER
  • ONAPRISTONE EXTENDED-RELEASE COMPOSITIONS AND METHODS
    Publication number: 20160166583
    Abstract: Onapristone extended-release formulations and methods of administering onapristone extended-release formulations are provided. Onapristone extended-release formulations provide sufficient therapeutic activity as compared to immediate-release formulations with reduced potential for adverse side effects.
    Type: Application
    Filed: November 16, 2015
    Publication date: June 16, 2016
    Inventors: Alexander Zukiwski, Stefan Proniuk
  • COMPOSITIONS AND THEIR USE IN ORAL DOSING REGIMENS
    Publication number: 20160166584
    Abstract: Described herein are oral pharmaceutical compositions and their use in testosterone replacement therapy applications.
    Type: Application
    Filed: January 22, 2016
    Publication date: June 16, 2016
    Applicant: Lipocine Inc.
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Satish Nachaegari, Srinivasan Venkateshwaran
  • COMPOSITIONS AND THEIR USE IN ORAL DOSING REGIMENS
    Publication number: 20160166585
    Abstract: Described herein are oral pharmaceutical compositions and their use in testosterone replacement therapy applications.
    Type: Application
    Filed: January 22, 2016
    Publication date: June 16, 2016
    Applicant: Lipocine Inc.
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Satish Nachaegari, Srinivasan Venkateshwaran
  • METHOD FOR TREATING A DEGENERATIVE DISEASE OF THE NERVOUS SYSTEM USING 3-METHOXY-PREGNENOLONE OR DERIVATIVES THEREOF
    Publication number: 20160166586
    Abstract: The present invention relates to a method for the treatment of a degenerative disease of the nervous system in a patient, comprising administering to said patient an effective quantity of 3?-methoxy-pregna-5-ene-20-one (3?-methoxy-PREG) or derivatives thereof.
    Type: Application
    Filed: November 24, 2015
    Publication date: June 16, 2016
    Applicant: MAPREG
    Inventors: Etienne-Emile BAULIEU, Esther FELLOUS, Paul ROBEL